BACKGROUND. In Lewy body diseases (LBDs) Parkinson disease (PD), and dementia with Lewy bodies (DLB), by the time parkinsonism or cognitive dysfunction manifests clinically, substantial neurodegeneration has already occurred. Biomarkers are needed to identify central LBDs in a preclinical phase, when neurorescue strategies might forestall symptomatic disease. This phase may involve catecholamine deficiency in the autonomic nervous system. We analyzed data from the prospective, observational, long-term PDRisk study to assess the predictive value of low versus normal cardiac ¹⁸F-dopamine positron emission tomography (PET), an index of myocardial content of the sympathetic neurotransmitter norepinephrine, in at-risk individuals.

中文翻译：

---

18F-多巴胺正电子发射断层扫描显示心脏去甲肾上腺素能缺乏，可识别临床前中枢路易体疾病

背景。在路易体病 (LBD)、帕金森病 (PD) 和路易体痴呆 (DLB) 中，当帕金森病或认知功能障碍在临床上表现出来时，实质上的神经变性已经发生。在临床前阶段，神经救援策略可能会预防症状性疾病，因此需要生物标志物来识别中枢 LBD。这个阶段可能涉及自主神经系统中儿茶酚胺缺乏。我们分析了前瞻性、观察性、长期 PDRisk 研究的数据，以评估低心脏¹⁸ F-多巴胺正电子发射断层扫描 (PET) 与正常心脏 18 F-多巴胺正电子发射断层扫描 (PET) 的预测价值，PET 是交感神经递质去甲肾上腺素心肌含量的指数。个人。